This information is intended for U.S. residents only.
A minimally absorbed (<0.4%) enteric antibiotic that targets noninvasive strains of Escherichia coli
- Minimal net impact on gut flora1
- Tolerability and safety comparable to placebo
- No clinically relevant resistance when used as directed2
- 20+ years of global use2
Proven to treat travelers’ diarrhea
- XIFAXAN® is indicated for the treatment of travelers’ diarrhea caused by noninvasive strains of Escherichia coli in patients at least 12 years of age
- Works in a unique way to target E. coli—halts overgrowth without overkill1,3
- E. coli is the most common cause of travelers’ diarrhea in Latin America, the Caribbean, and Africa4
- Stopped TD symptoms in 79.2% of patients*
- Approved in 33 countries, more than 500 clinical citations2
*In a randomized, double-blind, placebo-controlled study conducted in Mexico, Guatemala, and Kenya, the efficacy of XIFAXAN (200 mg orally 3 times a day for 3 days) was evaluated in 254 adult subjects with travelers' diarrhea. Stool specimens were collected before treatment and 1 to 3 days following the end of treatment to identify enteric pathogens, predominantly Escherichia coli. The clinical efficacy of XIFAXAN was assessed by the time to return to normal, formed stools and resolution of symptoms.
References
1. De Leo C, Eftimiadi C, Schito GC. Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin. Drugs Exp Clin Res. 1986;12:979-981.
2. Data on file, Salix Pharmaceuticals, Inc.
3. Huang DB, DuPont HL. Rifaximin—a novel antimicrobial for enteric infections. J Infect. 2005;50(2):97-106.
4. Yates J. Traveler's diarrhea. Am Fam Physician. 2005;71:2095-2100.
SAFETY CONSIDERATIONS
Xifaxan® (rifaximin) Tablets are indicated for the treatment of patients (≥12 years of age) with travelers’ diarrhea caused by noninvasive strains of
Escherichia coli. Xifaxan should not be used in patients with diarrhea complicated by fever or blood in the stool or diarrhea due to pathogens other than Escherichia coli. Xifaxan should be
discontinued if diarrhea symptoms get worse or persist more than 24-48 hours and alternative antibiotic therapy should be considered. Escherichia coli has been shown to develop resistance to rifaximin in vitro. However, the clinical significance of such an effect has not been studied.
In clinical trials, Xifaxan was generally well tolerated. The most common side effects (vs. placebo) were flatulence 11.3% (vs. 19.7%), headache 9.7% (vs. 9.2%), abdominal pain 7.2% (vs. 10.1%), rectal tenesmus 7.2%
(vs. 8.8%), defecation urgency 5.9% (vs. 9.2%) and nausea 5.3% (vs. 8.3%).
For complete Prescribing Information, please click here.
For product information, adverse event reports, and product complaint reports please call:
Salix Product Information Call Center
Phone: 1-800-508-0024
Fax: 1-510-595-8183
Email: